Prostaglandin E2 receptor, EP3, is induced in diabetic islets and negatively regulates glucose- and hormone- stimulated insulin secretion

Diabetes

Volumn 62, Issue 6, 2013, Pages 1904-1912

  Kimple, Michelle E ^a   Keller, Mark P ^b   Rabaglia, Mary R ^b   Pasker, Renee L ^a   Neuman, Joshua C ^b   Truchan, Nathan A ^a   Brar, Harpreet K ^a   Attie, Alan D ^b  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIC AMP; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLUCOSE; N [(5 BROMO 2 METHOXYPHENYL)SULFONYL] 3 [2 (2 NAPHTHYLMETHYL)PHENYL]ACRYLAMIDE; PROSTAGLANDIN E RECEPTOR 3; PROSTAGLANDIN E1; PROSTAGLANDIN E2; SULPROSTONE; GLUCAGON RECEPTOR; GLUCAGON-LIKE PEPTIDE-1 RECEPTOR; INSULIN; PTGER3 PROTEIN, MOUSE;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; INSULIN RELEASE; MOUSE; NONHUMAN; OBESITY; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; SIGNAL TRANSDUCTION; UPREGULATION; ANIMAL; DRUG ANTAGONISM; DRUG EFFECT; DRUG POTENTIATION; GENETICS; IN VITRO STUDY; METABOLISM; PANCREAS ISLET; SECRETION (PROCESS);

ANIMALS; DINOPROSTONE; FEMALE; GLUCOSE; HUMANS; INSULIN; INSULIN-SECRETING CELLS; ISLETS OF LANGERHANS; MICE; RECEPTORS, GLUCAGON; RECEPTORS, PROSTAGLANDIN E, EP3 SUBTYPE;

MLCS; MLOWN;

EID: 84878231693     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db12-0769     Document Type: Article

References (47)

1. Doyle ME, Egan JM. Mechanisms of action of glucagon-like peptide 1 in the pancreas. Pharmacol Ther 2007;113:546-593 (Pubitemid 46365961)
2. Blonde L, Montanya E. Comparison of liraglutide versus other incretinrelated anti-hyperglycaemic agents. Diabetes Obes Metab 2012; 14( Suppl. 2): 20-32
3. Aschner P, Kipnes MS, Lunceford JK, Sanchez M, Mickel C, Williams- Herman DE; Sitagliptin Study 021 Group. Effect of the dipeptidyl pepti-dase- 4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care 2006;29:2632-2637 (Pubitemid 44912190)
4. Raz I, Hanefeld M, Xu L, Caria C, Williams-Herman D, Khatami H; Sitagliptin Study 023 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus. Diabetologia 2006; 49: 2564-2571
5. Collet-Gaudillat C, Petit-Aubert G, Desforges-Bullet V, Beressi JP. Exenatide efficacy in unselected patients: comparison with clinical trials. J Diabetes Mellitus 2012; 2: 118-121
6. Clee SM, Attie AD. The genetic landscape of type 2 diabetes in mice. Endocr Rev 2007;28:48-83 (Pubitemid 46220850)
7. Keller MP, Choi Y, Wang P, et al. A gene expression network model of type 2 diabetes links cell cycle regulation in islets with diabetes susceptibility. Genome Res 2008;18:706-716 (Pubitemid 351645061)
8. Negishi M, Sugimoto Y, Namba T, Irie A, Narumiya S, Ichikawa A. Signal transductions of three isoforms of mouse prostaglandin E receptor EP3 subtype. Adv Prostaglandin Thromboxane Leukot Res 1995; 23: 255-257
9. Rabaglia ME, Gray-Keller MP, Frey BL, Shortreed MR, Smith LM, Attie AD. Alpha-Ketoisocaproate-induced hypersecretion of insulin by islets from diabetes-susceptible mice. Am J Physiol Endocrinol Metab 2005;289:E218-E224 (Pubitemid 41076621)
10. Doiron B, Cuif MH, Chen R, Kahn A. Transcriptional glucose signaling through the glucose response element is mediated by the pentose phosphate pathway. J Biol Chem 1996;271:5321-5324 (Pubitemid 26083863)
11. Bhatnagar S, Oler AT, Rabaglia ME, et al. Positional cloning of a type 2 diabetes quantitative trait locus; tomosyn-2, a negative regulator of insulin secretion. PLoS Genet 2011; 7: e1002323
12. Kimple ME, Joseph JW, Bailey CL, et al. Galphaz negatively regulates insulin secretion and glucose clearance. J Biol Chem 2008; 283: 4560-4567
13. Davis DB, Lavine JA, Suhonen JI, et al. FoxM1 is up-regulated by obesity and stimulates beta-cell proliferation. Mol Endocrinol 2010; 24: 1822 -1834
14. Sugimoto Y, Namba T, Honda A, et al. Cloning and expression of a cDNA for mouse prostaglandin E receptor EP3 subtype. J Biol Chem 1992; 267: 6463-6466
15. Negishi M, Sugimoto Y, Ichikawa A. Molecular mechanisms of diverse actions of prostanoid receptors. Biochim Biophys Acta 1995; 1259: 109-119
16. Belley M, Chan CC, Gareau Y, et al. Comparison between two classes of selective EP(3) antagonists and their biological activities. Bioorg Med Chem Lett 2006;16:5639-5642 (Pubitemid 44415443)
17. Belley M, Gallant M, Roy B, et al. Structure-activity relationship studies on ortho-substituted cinnamic acids, a new class of selective EP(3) antagonists. Bioorg Med Chem Lett 2005;15:527-530 (Pubitemid 40143119)
18. Hohmeier HE, Mulder H, Chen G, Henkel-Rieger R, Prentki M, Newgard CB. Isolation of INS-1-derived cell lines with robust ATP-sensitive K+ channel-dependent and -independent glucose-stimulated insulin secretion. Diabetes 2000;49:424-430 (Pubitemid 30131788)
19. Maida A, Lovshin JA, Baggio LL, Drucker DJ. The glucagon-like peptide-1 receptor agonist oxyntomodulin enhances beta-cell function but does not inhibit gastric emptying in mice. Endocrinology 2008; 149: 5670-5678
20. Kiriyama M, Ushikubi F, Kobayashi T, Hirata M, Sugimoto Y, Narumiya S. Ligand binding specificities of the eight types and subtypes of the mouse prostanoid receptors expressed in Chinese hamster ovary cells. Br J Pharmacol 1997;122:217-224 (Pubitemid 27397191)
21. Serre V, Dolci W, Schaerer E, et al. Exendin-(9-39) is an inverse agonist of the murine glucagon-like peptide-1 receptor: implications for basal intracellular cyclic adenosine 3′,5′-monophosphate levels and beta-cell glucose competence. Endocrinology 1998;139:4448-4454 (Pubitemid 28487758)
22. Sharp GW. Mechanisms of inhibition of insulin release. Am J Physiol 1996; 271: C1781 -C1799
23. Persaud SJ, Burns CJ, Belin VD, Jones PM. Glucose-induced regulation of COX-2 expression in human islets of Langerhans. Diabetes 2004;53(Suppl. 1):S190-S192 (Pubitemid 38168713)
24. Persaud SJ, Muller D, Belin VD, et al. The role of arachidonic acid and its metabolites in insulin secretion from human islets of langerhans. Diabetes 2007; 56: 197-203
25. Robertson RP. Dominance of cyclooxygenase-2 in the regulation of pancreatic islet prostaglandin synthesis. Diabetes 1998; 47: 1379-1383
26. Robertson RP, Chen M, McRae JR, Metz SA. Improvement of insulin secretion in diabetics by a prostaglandin synthesis inhibitor. Adv Exp Med Biol 1979; 119: 227-231
27. Robertson RP. Prostaglandins, glucose homeostasis, and diabetes mellitus. Annu Rev Med 1983; 34: 1-12
28. Shanmugam N, Todorov IT, Nair I, Omori K, Reddy MA, Natarajan R. Increased expression of cyclooxygenase-2 in human pancreatic islets treated with high glucose or ligands of the advanced glycation endproduct-specific receptor (AGER), and in islets from diabetic mice. Diabetologia 2006;49: 100-107 (Pubitemid 43151620)
29. Tran PO, Gleason CE, Robertson RP. Inhibition of interleukin-1betainduced COX-2 and EP3 gene expression by sodium salicylate enhances pancreatic islet beta-cell function. Diabetes 2002;51:1772-1778 (Pubitemid 34564289)
30. Parazzoli S, Harmon JS, Vallerie SN, Zhang T, Zhou H, Robertson RP. Cyclooxygenase-2, not microsomal prostaglandin E synthase-1, is the mechanism for interleukin-1β-induced prostaglandin E2 production and inhibition of insulin secretion in pancreatic islets. J Biol Chem 2012; 287: 32246-32253
31. Sawyer SJ, Norvell SM, Ponik SM, Pavalko FM. Regulation of PGE(2) and PGI(2) release from human umbilical vein endothelial cells by actin cytoskeleton. Am J Physiol Cell Physiol 2001; 281: C1038-C1045
32. Flores D, Liu Y, Liu W, Satlin LM, Rohatgi R. Flow-induced prostaglandin E2 release regulates Na and K transport in the collecting duct. Am J Physiol Renal Physiol 2012; 303: F632-F638
33. Kawai K, Yokota C, Ohashi S, Watanabe Y, Yamashita K. Evidence that glucagon stimulates insulin secretion through its own receptor in rats. Diabetologia 1995; 38: 274 -276
34. Robertson RP, Little SA. Down-regulation of prostaglandin E receptors and homologous desensitization of isolated adipocytes. Endocrinology 1983;113:1732-1738 (Pubitemid 13023814)
35. Shamma MS, Fernandez-Botran R, Suzuki T. PGE2-induced desensitization of adenylate cyclase of a murine macrophage-like cell line (P388D1). Prostaglandins 1988;36:329-341 (Pubitemid 18261633)
36. Coffey RG, Alberts VA, Weakland LL. Prostaglandin-dependent desensitization of human monocyte cAMP responses. J Leukoc Biol 1990; 48: 557-564
37. An S, Yang J, So SW, Zeng L, Goetzl EJ. Isoforms of the EP3 subtype of human prostaglandin E2 receptor transduce both intracellular calcium and cAMP signals. Biochemistry 1994; 33: 14496-14502
38. Negishi M, Sugimoto Y, Irie A, Narumiya S, Ichikawa A. Two isoforms of prostaglandin E receptor EP3 subtype. Different COOH-terminal domains determine sensitivity to agonist-induced desensitization. J Biol Chem 1993; 268:9517-9521 (Pubitemid 23146006)
39. Negishi M, Hasegawa H, Ichikawa A. Prostaglandin E receptor EP3gamma isoform, with mostly full constitutive Gi activity and agonist-dependent Gs activity. FEBS Lett 1996;386:165-168 (Pubitemid 26173070)
40. Aarab L, Siaume-Perez S, Chabardès D. Cell-specific coupling of PGE2 to different transduction pathways in arginine vasopressin- and glucagonsensitive segments of the rat renal tubule. Br J Pharmacol 1999;126:1041-1049 (Pubitemid 29103722)
41. Garrity MJ, Reed MM, Brass EP. Coupling of hepatic prostaglandin receptors to adenylate cyclase through a pertussis toxin sensitive guanine nucleotide regulatory protein. J Pharmacol Exp Ther 1989;248:979-983 (Pubitemid 19100744)
42. Kobayashi K, Murata T, Hori M, Ozaki H. Prostaglandin E2-prostanoid EP3 signal induces vascular contraction via nPKC and ROCK activation in rat mesenteric artery. Eur J Pharmacol 2011; 660: 375-380
43. Macias-Perez IM, Zent R, Carmosino M, Breyer MD, Breyer RM, Pozzi A. Mouse EP3 alpha, beta, and gamma receptor variants reduce tumor cell proliferation and tumorigenesis in vivo. J Biol Chem 2008; 283: 12538-12545
44. Irie A, Segi E, Sugimoto Y, Ichikawa A, Negishi M. Mouse prostaglandin E receptor EP3 subtype mediates calcium signals via Gi in cDNA-transfected Chinese hamster ovary cells. Biochem Biophys Res Commun 1994;204: 303-309 (Pubitemid 24335296)
45. Wang Z, Thurmond DC. Mechanisms of biphasic insulin-granule exocytosis - roles of the cytoskeleton, small GTPases and SNARE proteins. J Cell Sci 2009; 122: 893-903
46. Sanchez-Alavez M, Klein I, Brownell SE, et al. Night eating and obesity in the EP3R-deficient mouse. Proc Natl Acad Sci USA 2007;104:3009-3014 (Pubitemid 46327994)
47. Kimple ME, Moss JB, Brar HK, et al. Deletion of GαZ protein protects against diet-induced glucose intolerance via expansion of β-cell mass. J Biol Chem 2012; 287: 20344-20355